DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Q4 2020 13F-HR Holdings
Net value change ($000)
+952,881
(23.2%)
New positions
41
Sold out positions
22
Turnover %
54.6%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| VTRS | 294,668 | NEW |
| BIIB | 109,697 | NEW |
| Oncorus, Inc. | 92,107 | NEW |
| CALC | 86,144 | 128.3% |
| TOI | 58,968 | NEW |
| CareMax, Inc. | 53,333 | NEW |
| CYTK | 51,140 | NEW |
| SpringWorks Therapeutics, Inc. | 45,807 | 77.9% |
| RYTM | 39,792 | 96.8% |
| CNC | 39,246 | 36.8% |
Top Reduces (Value $000, Stocks/ETFs)
| Mylan II B.V. | -196,853 | -100.0% |
| IMMUNOMEDICS INC | -195,986 | -100.0% |
| Horizon Therapeutics Public Ltd Co | -142,369 | -100.0% |
| MyoKardia, Inc. | -95,976 | -100.0% |
| TOI | -58,277 | -51.0% |
| GKOS | -34,442 | -100.0% |
| EHTH | -26,339 | -100.0% |
| HOLX | -25,790 | -100.0% |
| VCEL | -25,606 | -92.7% |
| TCR2 THERAPEUTICS INC. | -24,384 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|